Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

Benzinga · 3d ago
Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.